Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.
The activity of omiganan pentahydrochloride (formerly MBI 226; a synthetic cationic peptide) was assessed against 1,437 recent clinical bacterial isolates and 214 recent clinical yeast isolates. The omiganan was highly active, and minimal bactericidal concentrations or minimal fungicidal concentrations were either equal to or two- to fourfold higher than MICs. Kill curve experiments showed a clear pattern of bactericidal activity.
The Jones Group/JMI Laboratories, Inc., North Liberty, Iowa 52317, USA. helio-sader@jmilabs.com
Helio S
HS
Sader
Kelley A
KA
Fedler
Robert P
RP
Rennie
Shelley
S
Stevens
Ronald N
RN
Jones
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000382:microbiology; D015169:Colony Count, Microbial; D004355:Drug Stability; D005615:Freezing; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D010406:Penicillins; C478918:omiganan pentahydrochloride; D010068:Oxacillin